HTG Molecular Diagnostics (OTCPK:HTGM.Q) - Cotización, noticias y análisis

Resumen de acción HTGM.Q

HTG Molecular Diagnostics, Inc. es una empresa de ciencias de la vida centrada en la medicina de precisión.

HTGM.Q fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

No tiene una capitalización de mercado significativa ($3K)

Alta volatilidad del precio de la acción en los últimos 3 meses

Los ingresos disminuyeron un 28.2% el año pasado.

Los últimos informes financieros tienen más de 6 meses

Competidores de HTG Molecular Diagnostics, Inc.

SOAFEE

OTCPK:SOFE

US$98.7k

Pear Therapeutics

OTCPK:PEAR.Q

US$142.0

MediXall Group

OTCPK:MDXL

US$138.0

InnovaQor

OTCPK:INQR

US$408.5k

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for HTG Molecular Diagnostics
Historical stock prices
Current Share Price	US$0.0025
52 Week High	US$3.24
52 Week Low	US$0.0013
Beta	2.98
1 Month Change	66.67%
3 Month Change	92.31%
1 Year Change	-99.90%
3 Year Change	-100.00%
5 Year Change	-100.00%
Change since IPO	-100.00%

Noticias y actualizaciones recientes

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

Rentabilidad de los accionistas

	HTGM.Q	US Healthcare Services	Mercado US
7D	0%	-0.8%	-0.7%
1Y	-99.9%	-8.1%	22.8%

Rentabilidad vs. Industria: HTGM.Q obtuvo unos resultados inferiores a los del sector US Healthcare Services , que el año pasado arrojó un rendimiento del -10.4%.

Rentabilidad vs. Mercado: HTGM.Q obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is HTGM.Q's price volatile compared to industry and market?
HTGM.Q volatility
HTGM.Q Average Weekly Movement	270.2%
Healthcare Services Industry Average Movement	9.8%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de HTGM.Q ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de HTGM.Q ha disminuido de 4147% a 270% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	54	John Lubniewski	www.htgmolecular.com

HTG Molecular Diagnostics, Inc. es una empresa de ciencias de la vida centrada en la medicina de precisión. La empresa ofrece instrumentos, consumibles y software que automatizan el procesamiento de muestras y perfilan diversas dianas moleculares. Sus paneles de perfiles moleculares comercializados incluyen el panel HTG Transcriptome; el panel de inmuno-oncología de precisión HTG EdgeSeq; el ensayo HTG EdgeSeq miRNA whole-transcriptome; el ensayo HTG EdgeSeq DLBCL cell of origin assay EU; el panel HTG EdgeSeq Oncology Biomarker; el panel HTG immune response; y el panel HTG mouse mRNA tumor response.

Resumen de fundamentos de HTG Molecular Diagnostics, Inc.

¿Cómo se comparan los beneficios e ingresos de HTG Molecular Diagnostics con su capitalización de mercado?
Estadísticas fundamentales de HTGM.Q
Capitalización bursátil	US$5.54k
Beneficios(TTM)	-US$20.15m
Ingresos (TTM)	US$6.21m

0.0x

Ratio precio-ventas (PS)

0.0x

Ratio precio-beneficio (PE)

¿Está HTGM.Q sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HTGM.Q
Ingresos	US$6.21m
Coste de los ingresos	US$11.13m
Beneficio bruto	-US$4.92m
Otros gastos	US$15.23m
Beneficios	-US$20.15m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-9.10
Margen bruto	-79.14%
Margen de beneficio neto	-324.28%
Ratio deuda/patrimonio	1,452.4%

¿Cómo se ha desempeñado HTGM.Q a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HTGM.Q

Recompensas

Análisis de riesgos

Competidores de HTG Molecular Diagnostics, Inc.

OTCPK:SOFE

US$98.7k

OTCPK:PEAR.Q

US$142.0

OTCPK:MDXL

US$138.0

OTCPK:INQR

US$408.5k

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83